San Diego-based mostly Viking Therapeutics marked by itself as a significant competitor while in the weight loss drug industry in February after revealing promising knowledge from a mid-phase demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when offered for a weekly injection and in March the